Trial intelligence / Profile preview

RhinoPHAGE-2A in Chronic Rhinosinusitis Associated with Staphylococcus aureus Infection

2024-516220-34-00Phase 2Withdrawn

Sponsor: Hirszfeld Institute of Immunology and Experimental Therapy
Start: Apr 2025
Modality: Live Biotherapeutic Products → Microbiome Therapeutics
Countries: 1

Overview

Phase 2, randomised trial of RhinoPHAGE-2A in chronic rhinosinusitis (CRS) (2 arms), sponsored by Hirszfeld Institute of Immunology and Experimental Therapy. Planned start Apr 2025; status: withdrawn.

Drugs

RhinoPHAGE-2A

Conditions

chronic rhinosinusitis (CRS)

Beyond the preview

Go deeper on 2024-516220-34-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2024-516220-34-00.